Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2226
Embotelladora Andina Series A
AKO.A
$3.75B
| $2.43M | ﹤0.01% |
156,000
+800
| +0.5% | +$11.8K |
|
2227
Editas Medicine
EDIT
$433M
| $2.43M | ﹤0.01% |
+82,100
| New | +$2.05M |
|
2228
Lincoln National
LNC
$8.7B
| $2.43M | ﹤0.01% |
+41,174
| New | +$2.42M |
|
2229
Interface
TILE
$2.19B
| $2.43M | ﹤0.01% |
146,406
+25,900
| +21% | +$417K |
|
2230
Cumberland Pharmaceuticals
CPIX
$117M
| $2.42M | ﹤0.01% |
469,338
+200
| +0% | +$1.06K |
|
|
SSKN
2231
DELISTED
Strata Skin Sciences
SSKN
| $2.41M | ﹤0.01% |
115,966
+1,015
| +0.9% | +$23K |
|
2232
Blackbaud
BLKB
$2.05B
| $2.4M | ﹤0.01% |
+30,197
| New | +$2.53M |
|
2233
Weyco Group
WEYS
$432M
| $2.4M | ﹤0.01% |
90,800
-7,000
| -7% | -$173K |
|
2234
LeMaitre Vascular
LMAT
$1.88B
| $2.39M | ﹤0.01% |
66,600
+500
| +0.8% | +$17.3K |
|
|
SFE
2235
DELISTED
Safeguard Scientifics, Inc.
SFE
| $2.39M | ﹤0.01% |
217,617
-10,983
| -5% | -$126K |
|
|
NGHC
2236
DELISTED
National General Holdings Corp
NGHC
| $2.39M | ﹤0.01% |
108,000
-7,300
| -6% | -$160K |
|
|
CVIA
2237
DELISTED
Covia Holdings Corporation Common Stock
CVIA
| $2.38M | ﹤0.01% |
1,167,456
+348,957
| +43% | +$563K |
|
2238
AAR Corp
AIR
$5.85B
| $2.38M | ﹤0.01% |
52,760
-116,000
| -69% | -$5.04M |
|
|
BCRH
2239
DELISTED
BLUE CAPITAL REINSURANCE HOLDINGS LTD.
BCRH
| $2.38M | ﹤0.01% |
346,208
+44,308
| +15% | +$311K |
|
2240
Genpact
G
$5.69B
| $2.37M | ﹤0.01% |
56,300
-172,600
| -75% | -$6.9M |
|
2241
Trex
TREX
$5.06B
| $2.37M | ﹤0.01% |
+52,800
| New | +$2.33M |
|
|
ACR
2242
ACRES Commercial Realty
ACR
$102M
| $2.37M | ﹤0.01% |
66,895
+4,927
| +8% | +$173K |
|
|
LAND
2243
Gladstone Land Corp
LAND
$358M
| $2.37M | ﹤0.01% |
182,763
+41,530
| +29% | +$510K |
|
|
BEDU
2244
DELISTED
Bright Scholar Education Holdings
BEDU
| $2.37M | ﹤0.01% |
67,000
+12,100
| +22% | +$448K |
|
2245
FerroAtlántica
GSM
$820M
| $2.36M | ﹤0.01% |
2,511,885
+552,694
| +28% | +$411K |
|
|
GCP
2246
DELISTED
GCP Applied Technologies Inc.
GCP
| $2.36M | ﹤0.01% |
103,900
-51,100
| -33% | -$1.1M |
|
|
HTLF
2247
DELISTED
Heartland Financial USA, Inc.
HTLF
| $2.36M | ﹤0.01% |
47,400
-120,000
| -72% | -$5.64M |
|
2248
Steris
STE
$22.7B
| $2.35M | ﹤0.01% |
15,442
-165,858
| -91% | -$24.3M |
|
2249
Ponce Financial Group
PDLB
$502M
| $2.34M | ﹤0.01% |
222,240
+1,953
| +0.9% | +$19.9K |
|
2250
Verra Mobility
VRRM
$717M
| $2.33M | ﹤0.01% |
166,851
-131,249
| -44% | -$1.88M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.